PMID: 11929394Apr 4, 2002Paper

Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation

Alimentary Pharmacology & Therapeutics
C E J SlootsR J Felt-Bersma

Abstract

There is a need for better tolerated drugs to normalize bowel function in chronic constipation. Prucalopride is a highly selective, specific, serotonin4 receptor agonist with enterokinetic properties. To evaluate the effects of prucalopride on bowel function, colonic transit and anorectal function in patients with chronic constipation. Twenty-eight patients were enrolled in this double-blind, placebo-controlled, crossover study (prucalopride: 1 mg, n=12; 2 mg, n=16). Patients kept a bowel function diary. Colonic transit times and anorectal function (anal manometry, rectal sensitivity and rectal compliance) were assessed. Prucalopride (1 mg) compared to placebo significantly increased the mean number of spontaneous complete, spontaneous and all bowel movements per week. Prucalopride (1 mg) significantly decreased the percentage of bowel movements with hard/lumpy stools and straining and increased the urge to defecate. Prucalopride (1 and 2 mg) decreased the mean total colonic transit time by 12.0 h (prucalopride 42.8 h vs. placebo 54.8 h; P=0.074). No statistically significant effects were found in any of the anorectal function parameters. Prucalopride was well tolerated. There were no clinically relevant changes in standard saf...Continue Reading

References

Mar 1, 1976·Gut·J H Cummings, H S Wiggins
Aug 1, 1989·Digestive Diseases and Sciences·J E EverhartL R White
Jan 1, 1987·Gastroenterology·A M MetcalfB G Wolff
Aug 1, 1987·Digestive Diseases and Sciences·R S Sandler, D A Drossman
Sep 1, 1968·Postgraduate Medical Journal·J M Hinton, J E Lennard-Jones
Nov 1, 1981·Diseases of the Colon and Rectum·P ArhanD Pellerin
Sep 1, 1993·Gastroenterology·N J TalleyL J Melton
May 1, 1997·Gastroenterology·G Adler, R M Schmid
Jul 1, 1997·Diseases of the Colon and Rectum·R J Felt-BersmaS G Meuwissen
Aug 8, 1997·The Journal of Biological Chemistry·J S MunzerN G Seidah
Apr 2, 1999·Trends in Pharmacological Sciences·M R BriejerS K Sarna
Apr 17, 1999·European Journal of Clinical Pharmacology·H EricssonC G Regårdh
Sep 7, 1986·The International Journal of Health Planning and Management·R Schulz, R Harrison
May 29, 1999·Gastroenterology·V F EckardtG Bernhard
Jul 14, 1999·Gut·E M Alstead
Aug 24, 1999·Gut·E CorazziariJ Toouli
Oct 13, 1999·Gut·P G Isaacson

❮ Previous
Next ❯

Citations

Apr 10, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·D T Beattie, J A M Smith
Jan 2, 2007·Diseases of the Colon and Rectum·Meagan M CostedioGary M Mawe
Aug 10, 2010·Current Gastroenterology Reports·Noriaki ManabeMichael Camilleri
May 20, 2004·Current Treatment Options in Gastroenterology·Vijayamalini Pampati, Ronald Fogel
Sep 9, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·John F JohansonBrigitte Nault
May 30, 2008·The New England Journal of Medicine·Michael CamilleriLieve Vandeplassche
Jan 27, 2005·Journal of Paediatrics and Child Health·B R SouthwellJ M Hutson
May 16, 2006·Digestive Diseases·Marcello Tonini, Fabio Pace
Jul 20, 2006·Digestive Diseases·Brian E Lacy, Kirsten Weiser
Jan 1, 2010·Clinical and Experimental Gastroenterology·Banny S WongMichael Camilleri
Nov 17, 2009·Drugs·James E Frampton
Apr 16, 2014·The American Journal of Gastroenterology·Anton EmmanuelRené Kerstens
Apr 30, 2010·Digestive Diseases and Sciences·Cornelius E J SlootsMartine De Pauw
Aug 3, 2010·Medizinische Klinik·Birgit AdamGuido Gerken
Mar 26, 2014·Expert Opinion on Pharmacotherapy·Maura Corsetti, Jan Tack
Dec 10, 2015·Expert Review of Gastroenterology & Hepatology·Gabrio BassottiMassimo Bellini
Jan 28, 2010·Expert Opinion on Pharmacotherapy·Michael Camilleri, Annemie Deiteren
Sep 19, 2012·Expert Opinion on Drug Metabolism & Toxicology·Jan Tack, Maura Corsetti
Sep 15, 2010·Expert Opinion on Investigational Drugs·Ola GhaithAla I Sharara
Apr 23, 2010·Expert Opinion on Investigational Drugs·Noriaki ManabeMichael Camilleri
Dec 3, 2015·Drugs·Karly P Garnock-Jones
Feb 22, 2011·Gastroenterology Clinics of North America·Robin C Spiller
Dec 21, 2004·Alimentary Pharmacology & Therapeutics·D Lesbros-PantoflickovaA L Blum
May 27, 2005·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·P G LeclereR A Lefebvre
Oct 1, 2010·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·P G DinningI J Cook
Feb 24, 2012·Alimentary Pharmacology & Therapeutics·J TackV Stanghellini
May 28, 2011·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M KanazawaS Fukudo
Dec 9, 2010·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·S S C RaoL Szarka
Oct 15, 2009·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·A V EmmanuelN J Talley
Dec 30, 2014·Expert Opinion on Pharmacotherapy·Kay DiederenMarc Alexander Benninga
Apr 30, 2016·Journal of Neurogastroenterology and Motility·Muhammad S SajidZinu Philipose
Aug 9, 2008·Current Opinion in Pharmacology·Daniel PohlMichael Fried
Jan 28, 2012·Therapeutic Advances in Gastroenterology·Eamonn M M Quigley
Jan 15, 2014·The Cochrane Database of Systematic Reviews·Maureen CoggraveJune D Cody
Jan 9, 2019·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Uday C GhoshalJayanthi Venkataraman
Jan 26, 2005·The American Journal of Gastroenterology·Michael A KammBrigitte Nault
Aug 14, 2009·Expert Review of Gastroenterology & Hepatology·Jan Tack
May 18, 2019·Expert Review of Clinical Pharmacology·Priya Vijayvargiya, Michael Camilleri
Dec 31, 2016·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Stefan Müller-LissnerBart Morlion
Mar 30, 2006·World Journal of Gastroenterology : WJG·Agata Mulak, Leszek Paradowski

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.